Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Prior to joining Sage, Ms. Andor held multiple positions ... Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Here are today's Five Things You Need to Know in Boston business news, including earthquakes, an AI bubble, stock crash, spurned suitors and multibillion-dollar M&A deals.

M&A specialists are eyeing a robust list of likely US takeover candidates, with a buoyant economy, strong buyer appetite and ...

International Growth Composite Portfolio declined by -7.08% gross of fees and -7.36% net of fees, outperforming MSCI All ...

US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a ...

Sage Therapeutics Inc.’s Wednesday presentation ... The Boston company may provide updates on commercialization plans for both products in its presentation planned for 10:30 Monday morning.

How is the scent of Tasmania likely to be received when Malano ultimately produces its aromatic homage to the island state?